Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
47 hedge funds and large institutions have $119M invested in Alpine Immune Sciences Inc in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 16 closing their positions.
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
2% less funds holding
Funds holding: 48 → 47 (-1)
18% less capital invested
Capital invested by funds: $145M → $119M (-$26.5M)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.62M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.88M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.67M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.08M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.32M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.38M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.1M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.66M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$1.4M |
ALPN Hedge Fund Activity: Q2 2021 in Review
47 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q2 2021, worth a combined $119M — down 18% from $145M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ALPN and 15 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 8 added.
The largest buyer was BlackRock, adding an estimated $5.62M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $3.32M sold.
- 47 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q2 2021, down from 48 in Q1 2021.
- Funds reported $119M of Alpine Immune Sciences Inc stock for Q2 2021, down 18% quarter-over-quarter.
- 15 funds opened new Alpine Immune Sciences Inc positions in Q2 2021 and 16 closed out, a net change of -1 holder.
- The largest Alpine Immune Sciences Inc buyer in Q2 2021 was BlackRock, an estimated $5.62M added.
- The largest Alpine Immune Sciences Inc seller in Q2 2021 was Soleus Capital Management, an estimated $3.32M sold.
Based on aggregated 13F filings for Q2 2021.